cortistatin-14 has been researched along with Endocrine-Gland-Neoplasms* in 2 studies
2 review(s) available for cortistatin-14 and Endocrine-Gland-Neoplasms
Article | Year |
---|---|
Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?
During the last two decades, research into the modulation of immunity by the neuroendocrine system has flourished, unravelling significant effects of several neuropeptides, including somatostatin (SRIH), and especially cortistatin (CST), on immune cells. Scientists have learnt that the diffuse neuroendocrine system can regulate the immune system at all its levels: innate immunity, adaptive immunity, and maintenance of immune tolerance. Compelling studies with animal models have demonstrated that some neuropeptides may be effective in treating inflammatory disorders, such as sepsis, and T helper 1-driven autoimmune diseases, like Crohn's disease and rheumatoid arthritis. Here, the latest findings concerning the neuroendocrine control of the immune system are discussed, with emphasis on SRIH and CST. The second part of the review deals with the immune response to neuroendocrine tumors (NETs). The anti-NET immune response has been described in the last years and it is still being characterized, similarly to what is happening for several other types of cancer. In parallel with investigations addressing the mechanisms by which the immune system contrasts NET growth and spreading, ground-breaking clinical trials of dendritic cell vaccination as immunotherapy for metastatic NETs have shown in principle that the immune reaction to NETs can be exploited for treatment. Topics: Animals; Endocrine Gland Neoplasms; Endocrine System; Endocrinology; Humans; Immunity; Models, Biological; Neuroendocrine Tumors; Neuropeptides; Somatostatin | 2012 |
Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field.
Somatostatin receptors (sst), somatostatin (SS) and cortistatin (CST) are widely expressed in the various systems in the human and rodent organisms and are "responsible" for maintaining homeostasis, which is essential for survival. Because of their broad expression pattern sst, SS and CST interactions may play regulatory roles in both physiology and pathophysiology in mammalian organisms. SS analogue treatment strategies as well as the use of SS analogues for diagnostic purposes have been established in diseases of different origins. This review focuses on the currently determined role for SS analogues in today's clinical practice and the potential clinical prospects for SS, CST and sst interactions in the future, with a focus on neuroendocrine and non-neuroendocrine tumours and immune-mediated diseases. Moreover, the role of new SS analogues and new insights in sst physiology will be discussed. Topics: Antineoplastic Agents, Hormonal; Endocrine Gland Neoplasms; Endocrine System Diseases; Humans; Immune System; Immune System Diseases; Neoplasms; Neuropeptides; Neurosecretory Systems; Radionuclide Imaging; Receptors, Somatostatin; Somatostatin | 2008 |